OSSIO Closes $38.5 Million Series C Funding

OSSIO Closes $38.5 Million Series C Funding

Woburn, Massachusetts – (work wire) –OSSIOLtd. , a fast-growing orthopedic implant know-how firm, introduced immediately that it has executed simply that Closed $38.5 million in Sequence C funding. Together with the participation of present shareholders, the spherical was led by MVM Companions, a Boston and London-based development fairness agency that invests in revolutionary, industrial healthcare firms that handle excessive unmet medical wants.

“We are delighted to receive this level of interest and commitment from an experienced and distinguished investment firm in the field of medical technology,” said OSSIO CEO, Brian Ferrer. “The additional funding will enable us to accelerate the adoption of more OSSIOfiber® Smart bone regeneration technology by orthopedic and pediatric surgeons in the United States. Specifically, we intend to use these funds to promote new product development, sales force expansion, patient awareness and medical education.”

All OSSIO implants are made with OSSIOfiber’s Smart Bone Regeneration Technology, a breakthrough in stabilization material that provides the first reliable solution to the shortcomings of permanent metal hardware, traditional absorbable implants and allografts, which combine unparalleled mechanical strength with incredibly natural bone healing. permanent implantation. Made from a proprietary mineral fiber matrix and held together by a naturally biodegradable polymer, this technology has the properties of a bio-integrative material that provides surgeons with a more biocompatible way to restore patient stability and mobility while leaving nothing permanent behind.

Designed for rapid bone growth, regeneration and replacement, OSSIOfiber Intelligent Bone Regeneration is the first of its kind implant material stronger than cortical bone. OSSIOfiber is designed to provide the force required for functional stabilization and allows full integration into the original anatomy without a negative biological response. OSSIOfiber implants use current tampon and surgical techniques.

More than 10,000 OSSIO fiber implants have already been used in orthopedics since their commercial introduction in 2019.

“We believe that OSSIO’s new bio-integration technology has the potential to transform the orthopedic fixation market,” said MVM. Dr. Stephen Readers. “We are excited to support the company’s mission to improve patient outcomes across a broad range of procedures.”

Dr. Readers and fellow MVM Dr. Kevin Cheng are joining the OSSIO Board of Directors as part of this funding.


OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, clinicians and payers. Founded in 2014, its vision is to provide the first reliable alternative to metal implants in the multibillion dollar global orthopedic fixation market through its smart OSSIOfiber bone regeneration technology. OSSIO development is headquartered in Caesarea, Israel, and its US headquarters are in Woburn, MA. For more information about the company, visit www.ossio.io.

The forward-looking statements made listed below are based mostly on the estimates and assumptions of OSSIO administration and are believed to be affordable, though they’re inherently unsure and tough to foretell.

About MVM Companions

MVM has invested within the high-growth healthcare enterprise since 1997. The corporate has a broad world funding outlook spanning medical know-how, prescription drugs, diagnostics, digital well being and different sectors of healthcare.

#OSSIO #Closes #Million #Sequence #Funding

Leave a Reply

Your email address will not be published.